| Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates BQ Shen, K Xu, L Liu, H Raab, S Bhakta, M Kenrick, KL Parsons-Reponte, ... Nature biotechnology 30 (2), 184-189, 2012 | 1095 | 2012 |
| Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats LA Khawli, S Goswami, R Hutchinson, ZW Kwong, J Yang, X Wang, Z Yao, ... MAbs 2 (6), 613-624, 2010 | 445 | 2010 |
| Effects of charge on antibody tissue distribution and pharmacokinetics CA Boswell, DB Tesar, K Mukhyala, FP Theil, PJ Fielder, LA Khawli Bioconjugate chemistry 21 (12), 2153-2163, 2010 | 429 | 2010 |
| Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges Y Vugmeyster, X Xu, FP Theil, LA Khawli, MW Leach World journal of biological chemistry 3 (4), 73, 2012 | 289 | 2012 |
| Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody–drug conjugates in rats CA Boswell, EE Mundo, C Zhang, D Bumbaca, NR Valle, KR Kozak, ... Bioconjugate chemistry 22 (10), 1994-2004, 2011 | 234 | 2011 |
| Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development J Tibbitts, D Canter, R Graff, A Smith, LA Khawli MAbs 8 (2), 229-245, 2016 | 175 | 2016 |
| Pivotal study of iodine-131–labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer S Chen, L Yu, C Jiang, Y Zhao, D Sun, S Li, G Liao, Y Chen, Q Fu, Q Tao, ... Journal of clinical oncology 23 (7), 1538-1547, 2005 | 160 | 2005 |
| Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate B LeBerthon, LA Khawli, M Alauddin, GK Miller, BS Charak, A Mazumder, ... Cancer Research 51 (10), 2694-2698, 1991 | 136 | 1991 |
| Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration Y Zheng, DB Tesar, L Benincosa, H Birnböck, CA Boswell, D Bumbaca, ... MAbs 4 (2), 243-255, 2012 | 135 | 2012 |
| Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics D Bumbaca, CA Boswell, PJ Fielder, LA Khawli The AAPS journal 14, 554-558, 2012 | 126 | 2012 |
| Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model CV Pastuskovas, EE Mundo, SP Williams, TK Nayak, J Ho, S Ulufatu, ... Molecular cancer therapeutics 11 (3), 752-762, 2012 | 124 | 2012 |
| Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors LA Khawli, GK Miller, AL Epstein Cancer 73 (S3), 824-831, 1994 | 108 | 1994 |
| A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components HM Kinnunen, V Sharma, LR Contreras-Rojas, Y Yu, C Alleman, ... Journal of Controlled Release 214, 94-102, 2015 | 104 | 2015 |
| Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations S Boune, P Hu, AL Epstein, LA Khawli Antibodies 9 (2), 22, 2020 | 103 | 2020 |
| A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors JL Hornick, J Sharifi, LA Khawli, P Hu, BH Biela, MM Mizokami, A Yun, ... Cancer biotherapy & radiopharmaceuticals 13 (4), 255-268, 1998 | 96 | 1998 |
| Modified antibodies LA Khawli, AL Epstein US Patent 5,194,594, 1993 | 96 | 1993 |
| Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors N Zhang, RE Sadun, RS Arias, ML Flanagan, SM Sachsman, YC Nien, ... Clinical cancer research 13 (9), 2758-2767, 2007 | 94 | 2007 |
| Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis P Hu, J Yan, J Sharifi, T Bai, LA Khawli, AL Epstein Cancer Research 63 (16), 5046-5053, 2003 | 93 | 2003 |
| Generation of rituximab polymer may cause hyper-cross-linking–induced apoptosis in non-Hodgkin's lymphomas N Zhang, LA Khawli, P Hu, AL Epstein Clinical cancer research 11 (16), 5971-5980, 2005 | 91 | 2005 |
| Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25+ T-cell depletion J Li, P Hu, LA Khawli, AL Epstein Cancer research 63 (23), 8384-8392, 2003 | 83 | 2003 |
